MILPREM-200
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MILPREM-200 (MILPREM-200).
MILPREM-200 is a dual inhibitor of the PI3K/AKT/mTOR pathway and the WNT/β-catenin signaling cascade, disrupting downstream effectors of cell proliferation and survival in tumors overexpressing these pathways.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2C9, with minor contributions from CYP2C8 and CYP1A2. Undergoes extensive oxidative metabolism with glucuronide conjugation. |
| Excretion | Renal excretion of unchanged drug (30-40%) and as glucuronide conjugate (10-15%); biliary/fecal excretion accounts for 20-30% as metabolites. |
| Half-life | Terminal elimination half-life is 12-18 hours (mean 15 hours); clinically, steady-state is reached after 3-5 days, and dosing adjustments are needed in renal impairment. |
| Protein binding | 98-99% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg (mean 1.0 L/kg), indicating extensive tissue distribution and moderate penetration into extravascular spaces. |
| Bioavailability | Oral: 60-70% (due to first-pass metabolism); intramuscular: 90-100%; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; intramuscular: 15-30 minutes; intravenous: within 5 minutes. |
| Duration of Action | Oral: 8-12 hours; intramuscular: 12-24 hours; intravenous: 4-8 hours. Clinical note: Duration may be prolonged in hepatic impairment. |
MILPREM-200: 200 mg orally once daily with food.
| Dosage form | TABLET |
| Renal impairment | eGFR >50 mL/min: no adjustment; eGFR 30-50 mL/min: 200 mg every 48 hours; eGFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce to 200 mg every 48 hours; Child-Pugh C: contraindicated. |
| Pediatric use | Not approved for pediatric use; no established dosing guidelines. |
| Geriatric use | Initiate at 200 mg every 48 hours; monitor renal function and adjust per renal adjustment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MILPREM-200 (MILPREM-200).
| Breastfeeding | Excreted in human milk in trace amounts; M/P ratio not established. Considered compatible with breastfeeding; use lowest effective dose for shortest duration. |
| Teratogenic Risk | First trimester: No evidence of teratogenicity in animal studies; limited human data, but no major malformations reported. Second and third trimesters: Risk of fetal nephrotoxicity and oligohydramnios with prolonged use; avoid after 32 weeks due to risk of premature ductus arteriosus closure. |
| Fetal Monitoring |
■ FDA Black Box Warning
Risk of severe and fatal hepatotoxicity; baseline and periodic liver function monitoring required. Risk of severe hypertension; blood pressure must be controlled prior to initiation and monitored regularly.
| Serious Effects |
["Absolute: Known history of severe drug-induced liver injury (DILI) or active hepatocellular disease.","Absolute: Severe uncontrolled hypertension (systolic >180 mmHg or diastolic >110 mmHg).","Relative: Concurrent use of strong CYP3A4 inhibitors or inducers unless dose adjustment is possible."]
| Precautions | ["Hepatotoxicity: Dose reduction or discontinuation for elevated transaminases or bilirubin.","Hypertension: Monitor blood pressure; hold if systolic >160 mmHg or diastolic >100 mmHg.","Cardiac effects: QT interval prolongation; avoid in congenital long QT syndrome or with drugs known to prolong QT.","Embryo-fetal toxicity: Advise effective contraception during and for 3 months after treatment.","Gastrointestinal toxicity: Severe diarrhea and colitis; monitor and manage with antidiarrheals or steroids."] |
Loading safety data…
| Monitor maternal renal function and blood pressure; fetal ultrasound for amniotic fluid volume and ductus arteriosus patency if used beyond 32 weeks. |
| Fertility Effects | Reversible inhibition of ovulation due to prostaglandin synthesis inhibition; no permanent effect on fertility. |